Comparison of medical costs among patients using adalimumab and infliximab: A retrospective study (COMPAIRS)

Inflammatory Bowel Diseases

Volumn 18, Issue 11, 2012, Pages 2043-2055

  Sussman, Daniel A ^a   Kubiliun, Nisa ^a   Mulani, Parvez M ^b   Chao, Jingdong ^b   Gillis, Carol A T ^b   Yang, Mei ^b   Lu, Mei ^c   T Abreu, Maria ^d  

^a UNIVERSITY OF MIAMI   (United States)

^b ABBOTT LABORATORIES   (United States)

^c ANALYSIS GROUP   (United States)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

adalimumab; Crohn's disease; healthcare costs; infliximab

Indexed keywords

ADALIMUMAB; INFLIXIMAB;

ADULT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; CROHN DISEASE; DRUG COST; DRUG EFFICACY; DRUG UTILIZATION; EMERGENCY WARD; FEMALE; FOLLOW UP; HEALTH CARE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROPENSITY SCORE; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; CROHN DISEASE; DISEASE MANAGEMENT; FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84867579461     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.22873     Document Type: Article

References (29)

1. Lix LM, Sussman DA, Kubilivn N, et al. Longitudinal study of quality of life and psychological functioning for active, fluctuating, and inactive disease patterns in inflammatory bowel disease. Inflamm Bowel Dis. 2008; 14: 1575-1584.
2. Gibson TB, et al. The direct and indirect cost burden of Crohn's disease and ulcerative colitis. J Occup Environ Med. 2008; 50: 1261-1272.
3. Longobardi T, Bernstein CN,. Health care resource utilization in inflammatory bowel disease. Clin Gastroenterol Hepatol. 2006; 4: 731-743.
4. Longobardi T, Jacobs P, Bernstein CN,. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol. 2003; 98: 1064-1072.
5. Hay JW, Hay AR,. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol. 1992; 14: 309-317.
6. Targan SR, et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 1997; 337: 1029-1035.
7. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
8. Hanauer SB, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 2006; 130: 323-333 quiz 591.
9. Rutgeerts P, et al. Scheduled maintenance treatment with infliximab is superior to episodic treatment for the healing of mucosal ulceration associated with Crohn's disease. Gastrointest Endosc. 2006; 63: 433-442 quiz 464.
10. Hanauer SB, et al. Advances in the management of Crohn's disease: economic and clinical potential of infliximab. Clin Ther. 1998; 20: 1009-1028.
11. Rutgeerts P, et al. Comparison of scheduled and episodic treatment strategies of infliximab in Crohn's disease. Gastroenterology. 2004; 126: 402-413.
12. Colombel JF, et al. Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease: results from the CHARM trial. Am J Gastroenterol. 2009; 104: 1170-1179.
13. Lindsay J, et al. Health-economic analysis: cost-effectiveness of scheduled maintenance treatment with infliximab for Crohn's disease-modelling outcomes in active luminal and fistulizing disease in adults. Aliment Pharmacol Ther. 2008; 28: 76-87.
14. Bodger K, Kikuchi T, Hughes D,. Cost-effectiveness of biological therapy for Crohn's disease: Markov cohort analyses incorporating United Kingdom patient-level cost data. Aliment Pharmacol Ther. 2009; 30: 265-274.
15. Yu AP, et al. Cost utility of adalimumab versus infliximab maintenance therapies in the United States for moderately to severely active Crohn's disease. Pharmacoeconomics. 2009; 27: 609-621.
16. D'Hoore W, Bouckaert A, Tilquin C,. Practical considerations on the use of the Charlson comorbidity index with administrative data bases. J Clin Epidemiol. 1996; 49: 1429-1433.
17. Feagan BG, et al. Annual cost of care for Crohn's disease: a payor perspective. Am J Gastroenterol. 2000; 95: 1955-1960.
18. Cohen RD, et al. The cost of hospitalization in Crohn's disease. Am J Gastroenterol. 2000; 95: 524-530.
19. Lichtenstein GR, et al. Remission in patients with Crohn's disease is associated with improvement in employment and quality of life and a decrease in hospitalizations and surgeries. Am J Gastroenterol. 2004; 99: 91-96.
20. Rubenstein JH, Chong RY, Cohen RD,. infliximab decreases resource use among patients with Crohn's disease. J Clin Gastroenterol. 2002; 35: 151-156.
21. Hanauer SB, et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 2002; 359: 1541-1549.
22. Sands BE, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 2004; 350: 876-885.
23. Lichtenstein GR, et al. Infliximab maintenance treatment reduces hospitalizations, surgeries, and procedures in fistulizing Crohn's disease. Gastroenterology. 2005; 128: 862-869.
24. Colombel JF, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 2007; 132: 52-65.
25. Sandborn WJ, et al. Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 2007; 56: 1232-1239.
26. Feagan BG, et al. Effects of adalimumab therapy on incidence of hospitalization and surgery in Crohn's disease: results from the CHARM study. Gastroenterology. 2008; 135: 1493-1499.
27. Peyrin-Biroulet L, et al. Efficacy and safety of tumor necrosis factor antagonists in Crohn's disease: meta-analysis of placebo-controlled trials. Clin Gastroenterol Hepatol. 2008; 6: 644-653.
28. Colombel JF, et al. Adalimumab safety in global clinical trials of patients with Crohn's disease. Inflamm Bowel Dis. 2009; 15: 1308-1319.
29. Regueiro M, et al. Infliximab dose intensification in Crohn's disease. Inflamm Bowel Dis. 2007; 13: 1093-1099.